AS1411-VH032 and homoAS1411 are novel tumor-targeting PROTACs that exploit AS1411 aptamer’s affinity for nucleolin to selectively degrade MDM2 in tumor cells, achieve effective tumor suppression with minimal toxicity, and offer a promising approach for precise and safe MDM2-targeted cancer therapy (Wang Z. et al., 2024). The gene discussed is MDM2; the disease is cancer.